Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Other Operating Expenses (2016 - 2025)

Xtant Medical Holdings has reported Other Operating Expenses over the past 16 years, most recently at $11.7 million for Q3 2025.

  • Quarterly Other Operating Expenses fell 1.21% to $11.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $34.6 million through Dec 2025, down 29.76% year-over-year, with the annual reading at $49.2 million for FY2024, 1238.79% up from the prior year.
  • Other Operating Expenses was $11.7 million for Q3 2025 at Xtant Medical Holdings, up from $11.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $15.2 million in Q4 2023 and troughed at -$20.0 million in Q4 2022.
  • The 5-year median for Other Operating Expenses is $5.3 million (2021), against an average of $4.8 million.
  • Year-over-year, Other Operating Expenses tumbled 477.02% in 2022 and then surged 659.62% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $5.3 million in 2021, then tumbled by 477.02% to -$20.0 million in 2022, then surged by 176.11% to $15.2 million in 2023, then dropped by 23.36% to $11.7 million in 2024, then increased by 0.53% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Other Operating Expenses are $11.7 million (Q3 2025), $11.6 million (Q2 2025), and $11.2 million (Q1 2025).